He has worked in the field of biologics for more than 10 years, especially antibody and cell gene therapy, focusing on process development and commercial production. The first Adamyumab analogue was listed in China in 2019, the Bevacizumab analogue was listed in China in 2021, the FDA and EMA successfully passed the BLA application, and the tozizumab analogue technology was transferred to MNC in 2021 and approved by FDA in 2023. In 2023, the key clinical process development and phase 1 clinical production of the first thalassemia cell gene therapy product in China will be completed. Participate in multiple hybrid and single-use workshops from conceptual design, construction delivery, validation to product PPQ. At the end of 2023, he joined Encore Immunization as senior Director of production, leading production process development and production-related work.